XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B | 10-Q: FY2025 Q2 Revenue: USD 29.04 M

LB filings
2025.08.13 11:44
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 29.04 M.

EPS: As of FY2025 Q2, the actual value is USD 0.5.

Segment Revenue

  • Income from Purchased Receivables under the EIR Method: $6,007,000 for the three months ended June 30, 2025, and $12,077,000 for the six months ended June 30, 2025.
  • Income from Purchased Receivables under the Cost Recovery Method: $1,743,000 for the three months ended June 30, 2025, and $7,268,000 for the six months ended June 30, 2025.
  • Revenue from Contracts with Customers: $5,025,000 for the three months ended June 30, 2025, and $9,025,000 for the six months ended June 30, 2025.
  • Revenue Recognized under Units-of-Revenue Method: $354,000 for the three months ended June 30, 2025, and $671,000 for the six months ended June 30, 2025.

Operational Metrics

  • Net Income: $9,191,000 for the three months ended June 30, 2025, and $11,558,000 for the six months ended June 30, 2025.
  • General and Administrative Expenses: $7,802,000 for the three months ended June 30, 2025, and $15,948,000 for the six months ended June 30, 2025.
  • Research and Development Expenses: $69,000 for the three months ended June 30, 2025, and $1,362,000 for the six months ended June 30, 2025.

Cash Flow

  • Net Cash Provided by Operating Activities: $8,668,000 for the six months ended June 30, 2025.
  • Net Cash Used in Investing Activities: - $26,674,000 for the six months ended June 30, 2025.
  • Net Cash Used in Financing Activities: - $9,925,000 for the six months ended June 30, 2025.

Unique Metrics

  • Investment in Equity Securities: $8,801,000 as of June 30, 2025.
  • Intangible Assets, Net: $45,434,000 as of June 30, 2025.

Future Outlook and Strategy

  • Core Business Focus: The company plans to continue its strategy as a biotech royalty aggregator, focusing on acquiring rights to future milestones, royalties, and commercial payments associated with partnered therapeutic candidates.
  • Non-Core Business: The company is involved in several acquisitions, including Turnstone, ESSA, LAVA, and HilleVax, which are expected to close in the near future, expanding its portfolio and potential revenue streams.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.